We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Sees Opportunity in Follow-on Biologics Pathway
Pfizer Sees Opportunity in Follow-on Biologics Pathway
April 29, 2009
Pfizer supports the creation of a pathway for follow-on biologics, and its pending purchase of Wyeth will give the company biotechnology manufacturing science capabilities that would be useful in developing generic proteins.